Citations (39)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (4)
Ervant J. Maksabedian Hernandez, Marlon Graf, Alexandria Portelli & Jason Shafrin. (2022) Estimating the impact of biosimilar entry on prices and expenditures in rheumatoid arthritis: a case study of targeted immune modulators. Journal of Medical Economics 25:1, pages 1118-1126.
Read now
Read now
Henry Grabowski, Genia Long, Richard Mortimer & Mehmet Bilginsoy. (2021) Continuing trends in U.S. brand-name and generic drug competition. Journal of Medical Economics 24:1, pages 908-917.
Read now
Read now
Henry Grabowski, Genia Long, Richard Mortimer & Ani Boyo. (2016) Updated trends in US brand-name and generic drug competition. Journal of Medical Economics 19:9, pages 836-844.
Read now
Read now
Iain Cockburn & Genia Long. (2015) The importance of patents to innovation: updated cross-industry comparisons with biopharmaceuticals. Expert Opinion on Therapeutic Patents 25:7, pages 739-742.
Read now
Read now
Articles from other publishers (35)
Joseph A. DiMasi, Zachary Smith, Ingrid Oakley-Girvan, Andrew Mackinnon, Mary Costello, Pamela Tenaerts & Kenneth A. Getz. (2022) Assessing the Financial Value of Decentralized Clinical Trials. Therapeutic Innovation & Regulatory Science 57:2, pages 209-219.
Crossref
Crossref
Georges Siotis, Carmine Ornaghi & Micael Castanheira. (2023) Evolving market boundaries and competition policy enforcement in the pharmaceutical industry. European Journal of Law and Economics.
Crossref
Crossref
Xingxian Luo, Lina Yang, Xin Du, Jingshu Yang, Feng Qian & Yue Yang. (2022) Analysis of Patent and Regulatory Exclusivity for Novel Agents in China and the United States: A Cohort Study of Drugs Approved Between 2018 and 2021. Clinical Pharmacology & Therapeutics 112:2, pages 335-343.
Crossref
Crossref
Saranrat Wittayanukorn, Matthew Rosenberg, Andreas Schick, Meng Hu, Zhong Wang, Andrew Babiskin, Robert Lionberger & Liang Zhao. (2020) Factors that have an Impact on Abbreviated New Drug Application (ANDA) Submissions. Therapeutic Innovation & Regulatory Science 54:6, pages 1372-1381.
Crossref
Crossref
William V. Padula, Sonal Parasrampuria, Mariana P. Socal, Rena M. Conti & Gerard F. Anderson. (2020) Market Exclusivity for Drugs with Multiple Orphan Approvals (1983–2017) and Associated Budget Impact in the US. PharmacoEconomics 38:10, pages 1115-1121.
Crossref
Crossref
Kirk W. Kerr & Lukas J. Glos. (2019) Effective Market Exclusivity of New Molecular Entities for Rare and Non-rare Diseases. Pharmaceutical Medicine 34:1, pages 19-29.
Crossref
Crossref
Jeffrey Fujimoto, Daniel M Tien, Sophie Snyder, Jeppe A Hertz & Stuart Schweitzer. (2019) The effect of patent expiration on sales of branded competitor drugs in a therapeutic class. Journal of Generic Medicines: The Business Journal for the Generic Medicines Sector 15:4, pages 177-184.
Crossref
Crossref
Micael Castanheira, Carmine Ornaghi & Georges Siotis. (2019) The unexpected consequences of generic entry. Journal of Health Economics 68, pages 102243.
Crossref
Crossref
Yucheng Ding & Xin Zhao. (2019) Pay-for-delay patent settlement, generic entry and welfare. International Journal of Industrial Organization 67, pages 102532.
Crossref
Crossref
Michael L. Lanthier, Kirk W. Kerr & Kathleen L. Miller. (2019) An Analysis of Follow‐On Development in New Drug Classes, January 1986–June 2018. Clinical Pharmacology & Therapeutics 106:5, pages 1125-1132.
Crossref
Crossref
Meng Hu, Andrew Babiskin, Saranrat Wittayanukorn, Andreas Schick, Matthew Rosenberg, Xiajing Gong, Myong‐Jin Kim, Lei Zhang, Robert Lionberger & Liang Zhao. (2019) Predictive Analysis of First Abbreviated New Drug Application Submission for New Chemical Entities Based on Machine Learning Methodology. Clinical Pharmacology & Therapeutics 106:1, pages 174-181.
Crossref
Crossref
Kyung-Bok Son, Ruth Lopert, Deborah Gleeson & Tae-Jin Lee. (2018) Moderating the impact of patent linkage on access to medicines: lessons from variations in South Korea, Australia, Canada, and the United States. Globalization and Health 14:1.
Crossref
Crossref
Kyung-Bok Son. (2018) Establishing healthy pharmaceutical regulations on statutory exclusivity: Lessons from the experience in the European Union, Canada, South Korea, Australia, and the United States. Journal of Generic Medicines: The Business Journal for the Generic Medicines Sector 14:4, pages 167-174.
Crossref
Crossref
Michael S. Sinha, Mehdi Najafzadeh, Elizabeth K. Rajasingh, James Love & Aaron S. Kesselheim. (2018) Labeling Changes and Costs for Clinical Trials Performed Under the US Food and Drug Administration Pediatric Exclusivity Extension, 2007 to 2012. JAMA Internal Medicine 178:11, pages 1458.
Crossref
Crossref
Paul Grootendorst, Minsup Shim, Adam Falconi, Tyler Robinson & Joel Lexchin. (2018) Intellectual Property Protection and Drug Plan Coverage: Evidence From Ontario. International Journal of Health Services 48:4, pages 702-715.
Crossref
Crossref
Gerard T. Vondeling, Qi Cao, Maarten J. Postma & Mark H. Rozenbaum. (2018) The Impact of Patent Expiry on Drug Prices: A Systematic Literature Review. Applied Health Economics and Health Policy 16:5, pages 653-660.
Crossref
Crossref
Xiaodong Guan, Ye Tian, Dennis Ross-Degnan, Chunxia Man & Luwen Shi. (2018) Interrupted time-series analysis of the impact of generic market entry of antineoplastic products in China. BMJ Open 8:7, pages e022328.
Crossref
Crossref
Y. Alatawi, Md. M. Rahman, N. Cheng, J. Qian, P. L. Peissig, R. L. Berg, C. D. Page & R. A. Hansen. (2018) Brand vs generic adverse event reporting patterns: An authorized generic-controlled evaluation of cardiovascular medications. Journal of Clinical Pharmacy and Therapeutics 43:3, pages 327-335.
Crossref
Crossref
Shinobu Imai, Kiyohide Fushimi & Karolina Andersson Sundell. (2018) Impact of new efficacy information on sales of antihypertensive medicines in Japan and Sweden. Health Policy and Technology 7:2, pages 194-199.
Crossref
Crossref
Bennett Levitan, Kenneth Getz, Eric L. Eisenstein, Michelle Goldberg, Matthew Harker, Sharon Hesterlee, Bray Patrick-Lake, Jamie N. Roberts & Joseph DiMasi. (2018) Assessing the Financial Value of Patient Engagement: A Quantitative Approach from CTTI’s Patient Groups and Clinical Trials Project. Therapeutic Innovation & Regulatory Science 52:2, pages 220-229.
Crossref
Crossref
Ali YurukogluEli LiebmanDavid B. Ridley. (2017) The Role of Government Reimbursement in Drug Shortages. American Economic Journal: Economic Policy 9:2, pages 348-382.
Crossref
Crossref
Henry Grabowski, Carlos Brain, Anna Taub & Rahul Guha. (2017) Pharmaceutical Patent Challenges: Company Strategies and Litigation Outcomes. American Journal of Health Economics 3:1, pages 33-59.
Crossref
Crossref
Richard Price & Genia Long. 2017. Decision Making in a World of Comparative Effectiveness Research. Decision Making in a World of Comparative Effectiveness Research
235
251
.
JA DiMasi & R Chakravarthy. (2016) Competitive Development in Pharmacologic Classes: Market Entry and the Timing of Development. Clinical Pharmacology & Therapeutics 100:6, pages 754-760.
Crossref
Crossref
Laura Park-Wyllie, Judy Van Stralen, Doron Almagor, Wendy Dobson-Belaire, Katia Charland, Andrew Smith & Jacques Le Lorier. (2016) Medication Persistence, Duration of Treatment, and Treatment-switching Patterns Among Canadian Patients Taking Once-daily Extended-release Methylphenidate Medications for Attention-Deficit/Hyperactivity Disorder: A Population-based Retrospective Cohort Study. Clinical Therapeutics 38:8, pages 1789-1802.
Crossref
Crossref
David B. RidleyStephane A. Régnier. (2016) The Commercial Market For Priority Review Vouchers. Health Affairs 35:5, pages 776-783.
Crossref
Crossref
Thomas Fulda, Alan Lyles & Albert WertheimerEarlene Lipowski. 2016. Pharmaceutical Public Policy. Pharmaceutical Public Policy
195
208
.
Joris Langedijk, Christopher J. Whitehead, Diederick S. Slijkerman, Hubert G.M. Leufkens, Marie-Hélène D.B. Schutjens & Aukje K. Mantel-Teeuwisse. (2016) Extensions of indication throughout the drug product lifecycle: a quantitative analysis. Drug Discovery Today 21:2, pages 348-355.
Crossref
Crossref
Joseph S. RossAaron S. Kesselheim. (2015) FDA Policy and Cardiovascular Medicine. Circulation 132:12, pages 1136-1145.
Crossref
Crossref
Jordan Paradise. (2021) The Legal and Regulatory Status of Biosimilars. American Journal of Law & Medicine 41:1, pages 49-84.
Crossref
Crossref
Henry G. GrabowskiJoseph A. DiMasiGenia Long. (2015) The Roles Of Patents And Research And Development Incentives In Biopharmaceutical Innovation. Health Affairs 34:2, pages 302-310.
Crossref
Crossref
Aidan Hollis & Peter Maybarduk. (2021) Antibiotic Resistance is a Tragedy of the Commons That Necessitates Global Cooperation. Journal of Law, Medicine & Ethics 43:S3, pages 33-37.
Crossref
Crossref
Robin Feldman. (2018) Perverse Incentives: Why Everyone Prefers High Drug Prices -- Except for Those Who Pay the Bills. SSRN Electronic Journal.
Crossref
Crossref
Frank P. Maier-Rigaud, Nathan Blalock & Oliver Gannon. (2016) Reverse Payments: An EU and US Perspective. SSRN Electronic Journal.
Crossref
Crossref
Ramsi Woodcock. (2015) Innovation, Litigation, and New Drugs. SSRN Electronic Journal.
Crossref
Crossref